{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T17:04:02Z","timestamp":1786727042538,"version":"build-2736575974"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1007\/s00296-015-3241-1","type":"journal-article","created":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T19:21:47Z","timestamp":1427916107000},"page":"1447-1459","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Efficacy of Raynaud\u2019s phenomenon and digital ulcer pharmacological treatment in systemic sclerosis patients: a systematic literature review"],"prefix":"10.1007","volume":"35","author":[{"given":"Paloma","family":"Garc\u00eda de la Pe\u00f1a Lefebvre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Betina","family":"Nishishinya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia Alejandra","family":"Pereda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Est\u00edbaliz","family":"Loza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter Alberto","family":"Sifuentes Giraldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Andr\u00e9s","family":"Rom\u00e1n Ivorra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Carreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I\u00f1igo","family":"R\u00faa-Figueroa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Mar\u00eda","family":"Pego-Reigosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Mu\u00f1oz-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,4,1]]},"reference":[{"key":"3241_CR1","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1136\/ard.2008.096677","volume":"68","author":"O Kowal-Bielecka","year":"2009","unstructured":"Kowal-Bielecka O, Landew\u00e9 R, Avouac J, Chwiesko S, Miniati I, Czirjak L et al (2009) EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 68:620\u2013628","journal-title":"Ann Rheum Dis"},{"key":"3241_CR2","unstructured":"Phillips B, Ball C, Sackett D, Badenoch D, Straus S, Haynes B, Dawes M (2001) Oxford centre for evidence-based medicine levels of evidence. BJU Int 2009 104:1825"},{"key":"3241_CR3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"AR Jadad","year":"1996","unstructured":"Jadad AR, Moore RA, Caroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ et al (1996) Assessing the quality of reports of randomized clinical trials is blinding necessary? Control Clin Trials 17:1\u201312","journal-title":"Control Clin Trials"},{"key":"3241_CR4","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1002\/1529-0131(200108)44:8<1841::AID-ART322>3.0.CO;2-8","volume":"44","author":"AE Thompson","year":"2001","unstructured":"Thompson AE, Shea B, Welch V, Fenlon D, Pope JE (2001) Calcium-channel blockers for Raynaud\u2019s phenomenon in systemic sclerosis. Arthritis Rheum 44:1841\u20131847","journal-title":"Arthritis Rheum"},{"key":"3241_CR5","first-page":"284","volume":"14","author":"CG Kallenberg","year":"1987","unstructured":"Kallenberg CG, Wouda AA, Kuitert JJ, Tijssen J, Wesseling H (1987) Nifedipine in Raynaud\u2019s phenomenon: relationship between immediate, short term and longterm effects. J Rheumatol 14:284\u2013290","journal-title":"J Rheumatol"},{"key":"3241_CR6","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1365-2133.1987.tb04122.x","volume":"117","author":"RHM Thomas","year":"1987","unstructured":"Thomas RHM, Rademaker M, Grimes SM, MacKay A, Kovacs IB, Cook ED, Bowcock SM, Kirby JD (1987) Nifedipine in the treatment of Raynaud\u2019s phenomenon in patients with systemic sclerosis. Br J Dermatol 117:237\u2013241","journal-title":"Br J Dermatol"},{"key":"3241_CR7","first-page":"77","volume":"197","author":"JM Varela-Aguilar","year":"1997","unstructured":"Varela-Aguilar JM, S\u00e1nchez-Rom\u00e1n J, Taleg\u00f3n MA, Castillo PMJ (1997) Comparative study of misoprostol and nifedipine in the treatment of Raynaud\u2019s phenomenon secondary to systemic diseases. Hemodynamic assessment with Doppler duplex. Rev Clin Esp 197:77\u201383","journal-title":"Rev Clin Esp"},{"key":"3241_CR8","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1365-2710.1988.tb00171.x","volume":"13","author":"SD Janini","year":"1988","unstructured":"Janini SD, Scott DG, Coppock JS, Bacon PA, Kendall MJ (1988) Enalapril in Raynaud\u2019s phenomenon. J Clin Pharm Ther 13:145\u2013150","journal-title":"J Clin Pharm Ther"},{"key":"3241_CR9","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.1002\/art.22965","volume":"56","author":"AE Gliddon","year":"2007","unstructured":"Gliddon AE, Dor\u00e9 CJ, Black CM, McHugh N, Moots R, Denton CP et al (2007) Prevention of vascular damage in scleroderma and autoimmune Raynaud\u2019s phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril. Arthritis Rheum 56:3837\u20133846","journal-title":"Arthritis Rheum"},{"key":"3241_CR10","first-page":"CD000953","volume":"2","author":"J Pope","year":"2000","unstructured":"Pope J, Fenlon D, Thompson A, Shea B, Furst D, Wells GA et al (2000) Iloprost and cisaprost for Raynaud\u2019s phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev 2:CD000953","journal-title":"Cochrane Database Syst Rev"},{"key":"3241_CR11","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1136\/bmj.298.6673.561","volume":"298","author":"M Rademaker","year":"1989","unstructured":"Rademaker M, Cooke ED, Almond NE, Beacham JA, Smith RE, Mant TG et al (1989) Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud\u2019s phenomenon in patients with systemic sclerosis: a double blind randomised study. BMJ 298:561\u2013564","journal-title":"BMJ"},{"key":"3241_CR12","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/1529-0131(199804)41:4<670::AID-ART14>3.0.CO;2-I","volume":"41","author":"FM Wigley","year":"1998","unstructured":"Wigley FM, Korn JH, Csuka ME, Medsger TA Jr, Rothfield NF, Ellman M et al (1998) Oral iloprost treatment in patients with Raynaud\u2019s phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study. Arthritis Rheum 41:670\u2013677","journal-title":"Arthritis Rheum"},{"key":"3241_CR13","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1093\/rheumatology\/37.9.952","volume":"37","author":"CM Black","year":"1998","unstructured":"Black CM, Halkier-S\u00f8rensen L, Belch JJ, Ullman S, Madhok R, Smit AJ et al (1998) Oral iloprost in Raynaud\u2019s phenomenon secondary to systemic sclerosis: a multicentre, placebo-controlled, dose-comparison study. Br J Rheumatol 37:952\u2013960","journal-title":"Br J Rheumatol"},{"key":"3241_CR14","first-page":"2173","volume":"26","author":"M Vayssairat","year":"1999","unstructured":"Vayssairat M (1999) Preventive effect of an oral prostacyclin analog, beraprost sodium, on digital necrosis in systemic sclerosis. French Microcirculation Society Multicenter Group for the Study of Vascular Acrosyndromes. J Rheumatol 26:2173\u20132178","journal-title":"J Rheumatol"},{"key":"3241_CR15","first-page":"503","volume":"19","author":"R Scorza","year":"2001","unstructured":"Scorza R, Caronni M, Mascagni B, Berruti V, Bazzi S, Micallef E et al (2001) Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud\u2019s phenomenon. A randomized, controlled study. Clin Exp Rheumatol 19:503\u2013508","journal-title":"Clin Exp Rheumatol"},{"key":"3241_CR16","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1002\/art.20676","volume":"50","author":"JH Korn","year":"2004","unstructured":"Korn JH, Mayes M, Matucci Cerinic M, Rainisio M, Pope J, Hachulla E et al (2004) Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 50:3985\u20133993","journal-title":"Arthritis Rheum"},{"key":"3241_CR17","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1136\/ard.2010.130658","volume":"70","author":"M Matucci-Cerinic","year":"2011","unstructured":"Matucci-Cerinic M, Denton CP, Furst DE, Mayes MD, Hsu VM, Carpentier P et al (2011) Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 70:32\u201338","journal-title":"Ann Rheum Dis"},{"key":"3241_CR18","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/rheumatology\/kep413","volume":"49","author":"VA Nguyen","year":"2010","unstructured":"Nguyen VA, Eisendle K, Gruber I, Hugl B, Reider D, Reider N (2010) Effect of the dual endothelin receptor antagonist bosentan on Raynaud\u2019s phenomenon secondary to systemic sclerosis: a double-blind prospective, randomized, placebo-controlled pilot study. Rheumatology (Oxford) 49:583\u2013587","journal-title":"Rheumatology (Oxford)"},{"key":"3241_CR19","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1161\/CIRCULATIONAHA.104.523324","volume":"112","author":"R Fries","year":"2005","unstructured":"Fries R, Shariat K, von Wilmowsky H, B\u00f6hm M (2005) Sildenafil in the treatment of Raynaud\u2019s phenomenon resistant to vasodilatory therapy. Circulation 112:2980\u20132985","journal-title":"Circulation"},{"key":"3241_CR20","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.3899\/jrheum.090270","volume":"36","author":"E Schiopu","year":"2009","unstructured":"Schiopu E, Hsu VM, Impens AJ, Rothman JA, McCloskey DA, Wilson JE et al (2009) Randomized placebo-controlled crossover trial of tadalafil in Raynaud\u2019s phenomenon secondary to systemic sclerosis. J Rheumatol 36:2264\u20132268","journal-title":"J Rheumatol"},{"key":"3241_CR21","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1093\/rheumatology\/keq291","volume":"49","author":"PD Shenoy","year":"2010","unstructured":"Shenoy PD, Kumar S, Jha LK, Choudhary SK, Singh U, Misra R et al (2010) Efficacy of tadalafil in secondary Raynaud\u2019s phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. Rheumatology (Oxford) 49:2420\u20132428","journal-title":"Rheumatology (Oxford)"},{"key":"3241_CR22","first-page":"CD000956","volume":"2","author":"J Pope","year":"2000","unstructured":"Pope J, Fenlon D, Thompson A, Shea B, Furst D, Wells G, Silman A (2000) Prazosin for Raynaud\u2019s phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev 2:CD000956","journal-title":"Cochrane Database Syst Rev"},{"key":"3241_CR23","first-page":"CD000954","volume":"2","author":"J Pope","year":"2000","unstructured":"Pope J, Fenlon D, Thompson A, Shea B, Furst D, Wells GA, Silman A (2000) Ketanserin for Raynaud\u2019s phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev 2:CD000954","journal-title":"Cochrane Database Syst Rev"},{"key":"3241_CR24","doi-asserted-by":"crossref","first-page":"3994","DOI":"10.1002\/art.20665","volume":"50","author":"RA Wise","year":"2004","unstructured":"Wise RA, Wigley FM, White B, Leatherman G, Zhong J, Krasa H, Kambayashi J et al (2004) Efficacy and tolerability of a selective alpha(2C)-adrenergic receptor blocker in recovery from cold-induced vasospasm in scleroderma patients: a single-center, double-blind, placebo-controlled, randomized crossover study. Arthritis Rheum 50:3994\u20134001","journal-title":"Arthritis Rheum"},{"key":"3241_CR25","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1001\/archderm.1984.01650390051010","volume":"120","author":"RS Surwit","year":"1984","unstructured":"Surwit RS, Gilgor RS, Allen LM, Duvic M (1984) A double-blind study of prazosin in the treatment of Raynaud\u2019s phenomenon in scleroderma. Arch Dermatol 120:329\u2013331","journal-title":"Arch Dermatol"},{"key":"3241_CR26","first-page":"94","volume":"12","author":"IJ Russell","year":"1985","unstructured":"Russell IJ, Lessard JA (1985) Prazosin treatment of Raynaud\u2019s phenomenon: a double blind single crossover study. J Rheumatol 12:94\u201398","journal-title":"J Rheumatol"},{"key":"3241_CR27","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1002\/art.24351","volume":"60","author":"L Chung","year":"2009","unstructured":"Chung L, Shapiro L, Fiorentino D, Baron M, Shanahan J, Sule S et al (2009) MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud\u2019s phenomenon: a randomized, controlled trial. Arthritis Rheum 60:870\u2013877","journal-title":"Arthritis Rheum"},{"key":"3241_CR28","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/art.1780280311","volume":"28","author":"HJ Williams","year":"1985","unstructured":"Williams HJ, Furst DE, Dahl SL, Steen VD, Marks C, Alpert EJ et al (1985) Double-blind, multicenter controlled trial comparing topical dimethyl sulfoxide and normal saline for treatment of hand ulcers in patients with systemic sclerosis. Arthritis Rheum 28:308\u2013314","journal-title":"Arthritis Rheum"},{"key":"3241_CR29","first-page":"CD000955","volume":"2","author":"J Pope","year":"2000","unstructured":"Pope J, Fenlon D, Thompson A, Shea B, Furst D, Wells G, Silman A (2000) Cyclofenil for Raynaud\u2019s phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev 2:CD000955","journal-title":"Cochrane Database Syst Rev"},{"key":"3241_CR30","first-page":"CD000955","volume":"2","author":"PC Tingey","year":"2000","unstructured":"Tingey PC, Harding SE, Pope J, Fenlon D, Furst D, Shea B et al (2000) Cyclofenil for Raynaud\u2019s phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev 2:CD000955","journal-title":"Cochrane Database Syst Rev"},{"key":"3241_CR31","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/j.0954-6820.1981.tb09842.x","volume":"210","author":"B Blom-Bulow","year":"1981","unstructured":"Blom-Bulow B, Oberg K, Wollheim FA, Persson B, Jonson B, Malmberg P et al (1981) Cyclofenil versus placebo in progressive systemic sclerosis. A one-year double-blind crossover study of 27 patients. Acta Medica Scandinavica 210:419\u2013428","journal-title":"Acta Medica Scandinavica"},{"key":"3241_CR32","first-page":"1801","volume":"35","author":"A Abou-Raya","year":"2008","unstructured":"Abou-Raya A, Abou-Raya S, Helmii M (2008) Statins: potentially useful in therapy of systemic sclerosis-related Raynaud\u2019s phenomenon and digital ulcers. J Rheumatol 35:1801\u20131808","journal-title":"J Rheumatol"},{"key":"3241_CR33","first-page":"349","volume":"18","author":"AL Herrick","year":"2000","unstructured":"Herrick AL, Hollis S, Schofield D, Rieley F, Blann A, Griffin K et al (2000) A double-blind placebo-controlled trial of antioxidant therapy in limited cutaneous systemic sclerosis. Clin Exp Rheumatol 18:349\u2013356","journal-title":"Clin Exp Rheumatol"},{"key":"3241_CR34","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1136\/ard.50.1.41","volume":"50","author":"MI Jayson","year":"1991","unstructured":"Jayson MI, Holland CD, Keegan A, Illingworth K, Taylor L (1991) A controlled study of stanozolol in primary Raynaud\u2019s phenomenon and systemic sclerosis. Ann Rheum Dis 50:41\u201347","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-015-3241-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-015-3241-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-015-3241-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,22]],"date-time":"2019-08-22T19:20:32Z","timestamp":1566501632000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-015-3241-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,1]]},"references-count":34,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["3241"],"URL":"https:\/\/doi.org\/10.1007\/s00296-015-3241-1","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,1]]}}}